Vitamin B 6 is important in fetal development, but little is known of the vitamin B 6 status of pregnant women and newborns in North America and potential modifying factors. This prospective study determined maternal and cord plasma concentrations of pyridoxal 5′ phosphate (PLP; an indicator of vitamin B 6 status) in a convenience sample of 368 Canadian pregnant women and their newborns. The association of maternal intake of vitamin B 6 and fetal genetic variants with cord plasma PLP and homocysteine concentrations was also examined. Dietary and supplemental intakes of vitamin B 6 were assessed in early and mid to late pregnancy. PLP concentrations were measured in maternal plasma in early pregnancy and at delivery, and in cord plasma. Six fetal variants of the MTHFR and CβS genes were assessed for their association with cord plasma PLP and homocysteine concentrations. Geometric mean (95% CI) PLP concentrations were 107 (98, 116) nmol/L in early pregnancy and 58 (53, 62) nmol/L at delivery, respectively, and 296 (275, 319) nmol/L in cord blood (p < .0001). During early pregnancy and at delivery, 3.6% and 5.5% of women had plasma PLP concentrations <20 nmol/L, respectively. Ninety eight percent of the women with supplemental B 6 intake of at least the recommended dietary allowance had PLP concentrations >20 nmol/L. Fetal genetic variants were not associated with cord PLP and homocysteine concentrations. Vitamin B 6 deficiency is uncommon in a cohort of Canadian pregnant women due largely to prevalent vitamin B 6 supplement use.
linked to adverse pregnancy and birth outcomes (Ronnenberg et al., 2002; Ronnenberg et al., 2007; Schuster, Bailey, & Mahan, 1981) , but not all studies have shown an association (Chen et al., 2015; Heller, Salkeld, & Körner, 1973) . A recent systematic review of four randomized controlled trials (Hillman, Cabaud, Nilsson, Arpin, & Tufano, 1963; Schuster, Bailey, & Mahan, 1984; Swartwout, Unglaub, & Smith, 1960; Temesvari, Szilagyi, Eck, & Boda, 1983) has found no convincing evidence to support maternal or neonatal clinical benefits of vitamin B 6 supplementation during pregnancy (Salam et al., 2015) .
The most widely used biomarker of vitamin B 6 status is PLP in plasma or serum because PLP reflects tissue stores of vitamin B 6 (Institute of Medicine, 1998) . A widely accepted cutoff to indicate suboptimal PLP status is <20 nmol/L, which was used to calculate the vitamin B 6 EAR for women aged 19-50 years (Institute of Medicine, 1998 intakes below the EAR; however, this figure drops to <5% in vitamin B 6 supplement users (Shakur, Tarasuk, Corey, & O'Connor, 2012) .
The 2003-2004 NHANES data indicated that~75% women of childbearing age using oral contraceptives had plasma PLP concentrations <20 nmol/L compared with~13% of men of the same age and~23% women of childbearing age not using oral contraceptives (Morris, Picciano, Jacques, & Selhub, 2008) . More recent NHANES data from 2005-2006 found vitamin B 6 to be the most common (~11%) micronutrient deficiency (as indicated by PLP <20 nmol/L), with a prevalence of~10% in females aged 20-39 years (Pfeiffer et al., 2013) . However, the prevalence of vitamin B 6 deficiency in pregnant women was not reported in this NHANES report (Pfeiffer et al., 2013) .
Maternal intake and blood concentrations of vitamin B 6 during pregnancy have not been well characterized. Although several experimental and observational studies have investigated PLP concentrations in maternal and cord plasma (Bjørke-Monsen et al., 2013; Chang, 1999; Chen et al., 2015; Fayyaz et al., 2014; Link & Zempleni, 1996; Lumeng, Cleary, Wagner, Yu, & Li, 1976; Schuster et al., 1984; Takimoto et al., 2007) , many date back two decades before widespread prenatal vitamin supplementation, and more recent studies did not measure cord plasma PLP. Therefore, we determined maternal and cord plasma concentrations of PLP in a cohort of pregnant Canadian women and their newborns and examined the association of maternal intake of dietary and supplemental vitamin B 6 with maternal and cord plasma concentrations of PLP. We also examined the association of six fetal single nucleotide polymorphisms (SNPs) in the MTHFR and CβS genes with cord plasma concentrations of PLP and homocysteine. Polymorphisms in the MTHFR and CβS genes, which are integrally related to vitamin B 6 in one-carbon metabolism, have previously been shown to affect plasma PLP and homocysteine concentrations in adults (Fredriksen et al., 2007) .
| PARTICIPANTS AND METHODS

| Subjects and study design
The study design, sample size rationale, and subject characteristics have been reported in detail previously . This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were ) to collect information regarding demographics and health status as described previously . Women in the study delivered between April 2011 and August 2012. At birth, the infants' anthropometric information was recorded.
| Assessment of dietary and supplemental intake
Maternal dietary intakes of vitamin B 6 and other one-carbon nutrients during early and late pregnancy were captured using a 110-item semiquantitative Block food frequency questionnaire (FFQ; NutritionQuest, Berkeley, CA) administered during the first (12-16 weeks of gestation) and second (35-37 weeks of gestation) study visits. Briefly, the Block FFQ is designed to capture the consumption of specific foods and beverages in the previous 3 months: for the present study, consumption between 0-and 16-week (early) and between 23-and 37-week (mid
Key messages
• Very little is known about vitamin B 6 status of pregnant women and their newborn infants.
• In our cohort of pregnant Canadian women, vitamin B 6 deficiency (PLP <20 nmol/L) was uncommon (6%).
• Vitamin B 6 supplements appear to be an important source of vitamin B 6 to ensure adequate maternal PLP concentrations during pregnancy.
• Failure to achieve optimal PLP concentrations with vitamin B 6 supplement suggests other metabolic and genetic factors might influence maternal and fetal PLP concentrations.
• Optimal vitamin B 6 status during pregnancy should be determined to ensure balance between the health benefits and risks to the growing fetus.
to late) pregnancy was measured. The Block FFQ has been validated for B vitamin intake in a sample of Ontarian women of reproductive age (34-36 years; Masih et al., 2015) . The median deattenuated Pearson correlation coefficient between the Block FFQ and two 24-hr recalls was reported to be 0.70 for vitamin B 6 from supplements and food (Boucher et al., 2006 
| Plasma PLP assay
Plasma PLP concentrations were determined by A/C Diagnostics LLC (San Diego, CA, USA) using a nonradioactive enzymatic assay (Han & Hoffman, 2008) . Samples were run in 96-well plates and analyzed on the Tecan Sunrise Microplate reader (Tecan Systems, San Jose, CA, USA) at an absorbance wavelength of 675 nm. The limit of detection was 10 nmol/L. Six calibrators (0, 12.5, 25.0, 100, 200, and 400 nmol/L) were used to establish linearity, and low and high controls were used for quality assurance. The Intra-Assay CVs (n = 23) for the low and high controls were 13.4% and 9.3%, respectively.
| DNA isolation and genotyping
DNA from cord blood MNCs was isolated using the DNA Isolation Kit for Mammalian Blood (Roche Diagnostics, Mannheim, Germany). The extracted DNA was >20 kb in all instances, was free of RNA contamination, and had an A 260/280 ratio between 1.8 and 2.0.
We examined the effects of six fetal SNPs in two genes on cord plasma PLP and homocysteine concentrations: rs1801133 and rs1801131 in the MTHFR gene, and rs234706, rs2124459, rs2851391, and rs4920037 in the CβS gene. The MTHFR C677T
(rs1801133) and CβS C699T (rs234706) SNPs have previously been
shown to affect plasma PLP and homocysteine concentrations in adults (Fredriksen et al., 2007) . We included other MTHFR (rs1801131) and
CβS polymorphisms (rs2124459, rs2851391 and rs4920037) based on their potential to modulate PLP or homocysteine concentrations.
MTHFR catalyzes the irreversible conversion of 5,10-methyleneTHF to 5-methylTHF (Institute of Medicine, 1998). CβS requires vitamin B 6 as a cofactor to convert homocysteine to cystathionine as the first irreversible step in the transsulfuration pathway (Institute of Medicine, 1998) . The MTHFR polymorphisms were genotyped using the TaqMan genotyping assay on an ABI Vii7 Biosystem (Applied Biosystems, Foster City, CA, USA) as described previously (von Ahsen, Oellerich, & Schutz, 2000) . The CβS polymorphisms were genotyped using the iPLEX Assay with the MassARRAY platform (Sequenom, San Diego, CA, USA) at the Clinical Genomics Centre (Toronto, Canada) as described previously (Ross, Hall, Smirnov, & Haff, 1998 ).
| Statistical analysis
As stated earlier, the aim of the PREFORM study was to determine the effects of maternal intake of folate and folic acid on DNA methylation of cord blood MNCs. The sample size for the PREFORM study was based on the power to detect a statistically significant association between red blood cell folate concentrations and global DNA methylation of cord blood MNCs. Therefore, for the primary outcome of the PREFORM study, a sample size of 260 mother-child pairs was estimated to provide 90% power to detect a correlation of ≥0.2 between red blood cell folate concentrations and global DNA methylation of cord blood MNCs . For the present study analyzing a secondary outcome concerning plasma PLP concentrations, we anticipated that if~10% of our women had plasma PLP concentrations <20 nmol/L, as reported for nonpregnant women (Pfeiffer et al., 2013) , 34 women in our sample would have suboptimal vitamin B6 status in early pregnancy. This would allow for three prognostic variables in the final statistical models examining the predictors of maternal plasma PLP concentrations <20 nmol/L.
Maternal and cord plasma PLP concentrations were log transformed to meet the assumptions of normality. Geometric mean with corresponding 95% CI was reported. Differences in plasma PLP concentrations at three time points (maternal plasma at recruitment, maternal plasma at delivery, and cord plasma) were analyzed using generalized estimating equations (PROC GENMOD) in order to take repeated measures into account. Student's t test was used to determine differences between vitamin B 6 supplement users and nonusers.
Correlations between dietary and blood parameters were assessed by Pearson correlation coefficients. To determine if changes in PLP concentration during pregnancy was dependent on maternal PLP concentration at 12-to 16-week gestation, the difference between PLP concentrations at delivery and at 12-to 16-week gestation was calculated. The nonparametric Wilcoxon test was used because the differences were skewed. For this analysis, early pregnancy PLP con- In all analyses, maternal plasma samples (n = 17) collected at delivery and cord plasma samples (n = 12 for PLP and n = 14 for homocysteine) were excluded from infants born <37-week gestation (preterm; n = 20). All tests were two-tailed, and an alpha level < .05 was considered statistically significant. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). All available data were included in analyses, and the samples size for each analysis was reported.
3 | RESULTS
| Characteristics of the study subjects and newborn infants
Detailed information on the PREFORM study design and characteristics of the study participants has been published previously . Of 1,315 pregnant women approached, 906 met eligibility criteria (healthy, 18-45 years of age, uncomplicated singleton pregnancy, <16-week post-conception at the time of enrolment). Women were excluded if they were taking medications known to interfere with folate metabolism, planned to deliver at another hospital, or planned to bank umbilical cord blood. After applying these exclusion criteria, 368 pregnant women enrolled in the study, and 309 deliveries occurred , 2015) . Briefly, the PREFORM study consisted of primarily nulliparous (54%), Caucasian (45%), university educated (62%) pregnant women, with the mean (±SD) age of 32 ± 5 years. Only a small proportion of women (<11.0%) reported household income below the poverty line. The mean (±SD) newborn gestational age was 39.3 ± 1.7 weeks. Approximately 85% of women who completed the early pregnancy visit remained in the study at delivery. The primary reason given for not continuing in the study was transfer or delivery at another hospital or moved away (n = 24). Furthermore, maternal plasma samples (n = 17) collected at delivery and cord plasma samples (n = 12 for PLP, n = 14 for homocysteine) were excluded from infants born <37 weeks of gestation (preterm; n = 20).
Birth weight, length, and head circumference were 3,346 ± 540 g, 52 ± 3 cm, and 34.2 ± 1.8 cm, respectively. There were no differences in gestational age at birth, sex of infant, birth weight, birth length, or head circumference between newborns from mothers who used Bvitamin containing supplements throughout pregnancy and those from mothers who did not .
| Dietary and supplemental intakes of vitamin B 6
Detailed information on dietary and supplemental intakes of vitamin B 6 and other one-carbon nutrients of the PREFORM study participants has been published previously . Briefly, the mean (±SD) maternal dietary vitamin B 6 intakes were slightly higher than the EAR (1.6 mg per day) in early (1.8 ± 0.9 mg per day) and mid to late (1.7 ± 0.7 mg per day) pregnancy . Eighty-seven percent of the women reported using a vitamin B 6 -containing supplement in early pregnancy, mostly in the form of a prenatal multivitamin formulation containing 1.9 mg of vitamin B 6 .
Ninety-one percent and 0.3% women had supplemental vitamin B 6
intakes at the RDA (1.9 mg per day) and tolerable upper limit (100 mg per day), respectively, in early pregnancy . In addition, 32 (8.7%) women reported taking Diclectin ® in early pregnancy to reduce nausea. Self-reported supplemental vitamin use in mid to late pregnancy was only reported as a categorical variable (yes/no) and hence, no supplemental vitamin B 6 intake dosages were reported for late pregnancy. Eighty-seven percent of the women reported using a vitamin B 6 -containing supplement in mid to late pregnancy. We have previously reported homocysteine concentrations in maternal plasma in early pregnancy and at delivery, and cord plasma from the PREFORM study . In maternal plasma, PLP concentrations were inversely, albeit weakly, correlated with homocysteine concentrations at delivery (r = −.15, p = .01) but not in early pregnancy. In cord plasma, PLP concentrations were weakly inversely, albeit nonsignificantly, correlated with homocysteine concentrations (r = −.13, p = .06). Note. CβS = cystathionine-β-synthase; Hcy = homocysteine; MTHFR = methylene tetrahydrofolate reductase; PLP = pyridoxal 5′ phosphate; SNP = single nucleotide polymorphism.
| Maternal and cord plasma PLP concentrations
| Association of maternal dietary and supplemental vitamin B 6 intakes with plasma PLP concentrations
*Differences between genotypes were assessed using least squares regression with fetal genotype as the explanatory variable and cord plasma PLP or homocysteine concentrations as the outcome variable.
| DISCUSSION
In a cohort of demographically diverse pregnant women receiving prenatal care in Toronto, Ontario, >85% of whom were taking a periconceptional vitamin B 6 -containing supplement, with the most common dose of 1.9 mg per day, only <6% had plasma PLP concentrations <20 nmol/L during pregnancy, a commonly used cutoff for low vitamin B 6 status (Institute of Medicine, 1998) . Previous observational studies have reported both larger (16% in Singapore; Chen et al., 2015; Takimoto et al., 2007) and smaller (0% and 0.2% in 1st and 2nd trimesters, respectively, in Canada; Fayyaz et al., 2014) proportions of pregnant women with plasma PLP concentrations <20 nmol/L. Although <20 nmol/L is generally used as the deficiency PLP cut off, others have suggested <30 nmol/L to indicate suboptimal PLP (Institute of Medicine, 1998). In our cohort, 6.8% and 14.3% of women had plasma PLP <30 nmol/L in early pregnancy and at delivery, respectively. A study from Japan found 16%, 82%, and 84% of pregnant women had plasma PLP concentrations <30 nmol/L in the 1st, 2nd, and 3rd trimesters, respectively (Shibata et al., 2013) . This is not surprising considering these women were not taking supplements, and their dietary vitamin B 6 intakes were considerably low (<1.0 mg per day; Shibata et al., 2013) .
Another Japanese study reported 100% of pregnant women had plasma PLP concentrations <30 nmol/L, again likely relating to lower vitamin B 6 intake compared with North America (Takimoto et al., 2007) .
The functional and clinical significance of the cutoff plasma PLP concentration for low vitamin B 6 status still remains to be clarified (Simpson, Bailey, Pietrzik, Shane, & Holzgreve, 2010) . Metabolic balance studies involving subjects intravenously supplemented with vitamin B 6 for 4 weeks determined health risks such as seborrheic dermatitis, microcytic anemia, and epileptiform convulsions (Institute of Medicine, 1998) were not apparent in subjects with plasma PLP concentrations >20 nmol/L (Institute of Medicine, 1998; Lui, Lumeng, Aronoff, & Li, 1985) . However, it is still unknown whether it is optimal to maintain plasma PLP concentrations >20 nmol/L during pregnancy (Simpson et al., 2010) . Few clinical studies have suggested that high vitamin B 6 status during pregnancy is associated with decreased prenatal nausea and vomiting (Babaei & Foghaha, 2014; Sahakian, Rouse, Sipes, Rose, & Niebyl, 1991; Vutyavanich, Wongtra-ngan, & Ruangsri, 1995) , higher Apgar scores (Schuster et al., 1984; Temesvari et al., 1983 ), higher birth weights (Chang, 1999) , reduced incidence of preeclampsia (de la Calle et al., 2003) and preterm birth (Ronnenberg et al., 2002) , and a protection against orofacial clefts (Krapels et al., 2004 ) and cardiovascular malformations (Czeizel, Puho, Banhidy, & Acs, 2004; Salam et al., 2015) . However, these purported associations have not unequivocally been demonstrated (Chen et al., 2015; Heller et al., 1973; Salam et al., 2015) .
Maternal plasma PLP concentrations decreased from early to late pregnancy in our study, which is consistent with previous observations (Fayyaz et al., 2014; Shibata et al., 2013; Takimoto et al., 2007) . Interestingly, there were distinct opposing trends across pregnancy depending on the mother's plasma PLP status in early pregnancy:
Plasma PLP concentrations increased during pregnancy in those with plasma PLP concentrations <20 nmol/L in early pregnancy, and the opposite trend was observed in those with plasma PLP concentrations ≥20 nmol/L in early pregnancy. However, this observation could be a chance finding as the sample size for those with plasma PLP concentrations <20 nmol/L was small. Also, we cannot rule out the statistical phenomenon "regression to the mean" as an explanation for this observation (Barnett, van der Pols, & Dobson, 2005) . It is possible that those with lower PLP concentrations in early pregnancy were low responders who required prolonged vitamin B6 supplementation to increase plasma PLP concentrations. Our overall observation of decreasing plasma PLP during pregnancy is likely related to normal physiological changes associated with pregnancy rather than diminished vitamin B 6 status. Plasma PLP concentrations are known to decrease during pregnancy likely due to increased plasma volume (Institute of Medicine, 1998) and fetal sequestering of PLP for rapid fetal growth and development (Simpson et al., 2010) . However, the observed decrease in our study is unlikely related solely to hemodilu- plasma PLP concentrations at pre-pregnancy or first trimester levels (Chang, 1999; Lumeng et al., 1976; Schuster et al., 1984) . Approximately 10% of the participants reported using Diclectin ® containing 10 mg pyridoxine hydrochloride during early pregnancy to reduce pregnancy-associated nausea. Most of these women stopped using Adequate dietary intakes and prevalent supplemental use of vitamin B 6 in the present study likely contributed to higher plasma PLP concentrations compared with previous studies from other countries (Bjørke-Monsen et al., 2013; Chen et al., 2015; Link & Zempleni, 1996; Takimoto et al., 2007) . However, different assays (HPLC and enzymatic) employed across published studies, and limitations associated with these assays preclude direct comparison of our data with others (Rybak, Jain, & Pfeiffer, 2005) . Furthermore, fortification practices might have contributed to the discrepancy. In Canada, the addition of 0.31 mg vitamin B 6 per 100 g flour and 0.6 mg per 100 g of breakfast cereal is an optional and yet widespread fortification practice (Barr, DiFrancesco, & Fulgoni, 2013; Canada Food Inspection Agency, 2009 ). In our study cohort, breakfast cereals were the highest ranked fortified food contributing to total vitamin B 6 intake in early pregnancy . Indeed, a recent Canadian study has reported comparable maternal PLP concentrations (median 94, 95% CI [82, 112] nmol/L and 76, 95% [CI 70, 83] nmol/L in first and second trimesters, respectively) to the present study (Fayyaz et al., 2014 Similar to a previous study (Obeid, Munz, Jager, Schmidt, & Herrmann, 2005) , cord plasma PLP concentrations were five times the maternal plasma PLP concentrations at delivery. A small observational study (n = 31) from Germany reported much lower cord plasma PLP concentrations (mean ± SD: 64 ± 39 nmol/L) compared with the present study (Link & Zempleni, 1996) . Three clinical trials have reported that maternal vitamin B 6 supplementation increases cord plasma PLP concentrations in a dose-dependent manner (Chang, 1999; Lumeng et al., 1976; Schuster et al., 1984) . These studies have also observed that PLP concentrations are higher in cord plasma than in maternal plasma at delivery (Chang, 1999; Lumeng et al., 1976; Schuster et al., 1984) .
Placental perfusion studies have shown vitamin B 6 is converted to its active form and then actively transferred to the fetus (Cleary, Lumeng, & Li, 1975; Schenker, Johnson, Mahuren, Henderson, & Coburn, 1992) .
In a large-scale Norwegian study of adults, the T variant in the MTHFR C677T SNP was associated with a significant increase in plasma homocysteine and a decrease in plasma PLP (Fredriksen et al., 2007) . The CβS 699C > T polymorphism was negatively associated with plasma homocysteine concentrations (Fredriksen et al., 2007) . However, none of the six fetal genotypes was associated with cord plasma PLP concentrations in our population. One possible explanation is that most of the women were well saturated with vitamin B6, masking associations. Associations might become apparent at lower vitamin B6 status, which have previously been observed for folate . Hormonal influences, hemodilution, and increased fetal demand for PLP may exert a stronger influence on PLP and homocysteine in cord plasma and may explain why we failed to see an association. Another explanation for the lack of association may be insufficient statistical power due to the small sample size. In contrast to these null findings, maternal plasma PLP concentrations at delivery were significantly associated with cord plasma PLP concentrations.
Taken together, these data suggest that maternal plasma PLP concentrations may exert a greater influence on cord plasma PLP concentrations than fetal genotype at the time of birth.
The PREFORM study is a large comprehensive observational study assessing maternal and cord plasma vitamin B 6 status in a demographically diverse group of pregnant Canadian women and their infants. This is the first study to assess the potential modifying effects of maternal dietary and supplemental intake of vitamin B 6 including an important source of medicinal vitamin B 6 (Diclectin ® ) and fetal genotypes on cord plasma PLP concentrations. However, there are several limitations associated with our study. Although the PREFORM cohort reflects demographically diverse pregnant women in Toronto, they were highly educated (62% with university education), and only a small portion (<11%) reported a household income below the poverty line.
As such, our study participants may not represent pregnant Canadian or North American women. Although we examined six fetal genotypes in our analysis, we did not interrogate other fetal genetic variants in several vitamin B 6 dependent enzymes such as serine hydroxymethyltransferase and other enzymes known to affect PLP concentrations such as alkaline phosphatase and aldehyde oxidase (Carter et al., 2015; Hazra et al., 2009; Ueland, Ulvik, Rios-Avila, Midttun, & Gregory, 2015 (Han & Hoffman, 2008) used in the present study is associated with lower precision and accuracy compared with other PLP assays (HPLC and enzymatic) and tends to underestimate deficiency (Lamers, 2011; Rybak et al., 2005) . Plasma PLP concentrations were determined in nonfasting maternal blood samples. As vitamin B 6 and protein intake (Leklem, 1990; Miller, Leklem, & Shultz, 1985) can influence PLP concentrations, standardized collection of fasting blood samples would have been more ideal.
Because study subjects were recruited and the initial blood was drawn from those agreeing to participate during their first visit to obstetricians, we could not limit the recruitment to those who had been fasting. Also, as blood was taken from the participants when they presented for delivery, we could not enforce the fasting state. However, we recorded the time of last meal and/or supplement use in early pregnancy, and the average (±SD) length of time food and/or supplements was consumed prior to blood draw was 5.2 ± 2.4 hr. A sensitivity analysis showed that plasma PLP concentrations were not significantly different between those who had blood taken <5 hr and those who had blood taken >5 hr after their last meal or supplemental intake (p = .42). The same relationship was found using 8 and 12 hr fasted as cutoffs (p = .19 and p = .07, respectively). However, we cannot rule out a possibility that there might be a higher proportion of women with plasma PLP concentrations >20 nmol/L relating to the transient increase in PLP concentrations following vitamin B 6 intake from food or supplements because we measured PLP concentrations in a nonfasting state. We did not measure other functional indicators of vitamin B 6 status such as transaminase activity or kynurenines concentrations in the present study (Ueland et al., 2015) . However, the measurements of these indicators are not widely available. Lastly, although vitamin B 6 supplement use was assessed using the Baseline Demographic and Health Questionnaire based on the Canadian Community Health Survey, Cycle 2.2 and the Block FFQ, we acknowledge that even very precise questionnaires have a limited ability to identify correctly subjects who regularly take micronutrient supplements as shown by previous research (Bates et al., 1998) .
In the present study, 94% of a cohort of pregnant Canadian women had plasma PLP concentrations ≥20 nmol/L. The EAR for vitamin B 6 during pregnancy is 1.6 mg per day (Institute of Medicine, 1998), corresponding to the median intake of the PREFORM study participants in early and mid to late pregnancy .
This suggests that inadequate vitamin B 6 intakes, from dietary sources only, in at least one-half of the PREFORM study participants . However, 100% of the pregnant Canadian women met the EAR through B 6 supplement use alone. Furthermore, 91% of the pregnant Canadian women met the RDA through B 6 supplement use alone. Ninety eight percent of the women with vitamin B 6 supplemental intake of at least the RDA had plasma PLP concentrations ≥20 nmol/L. Therefore, vitamin B 6 supplements appear to be an important source of vitamin B 6 to ensure adequate maternal PLP concentrations during pregnancy. However, up to 6% of pregnant women failed to achieve optimal PLP concentrations during pregnancy even with vitamin B 6 supplement (73% and 93% of women with plasma PLP <20 nmol/L in early and mid to late pregnancy, respectively) and Diclectin ® use, suggesting other metabolic and genetic factors might be responsible for this observation. The effects of prenatal vitamin B 6 status on pregnancy and birth outcomes and on health outcomes of the offspring have not yet been clearly established. Therefore, optimal vitamin B 6 status during pregnancy should be determined to ensure balance between the health benefits and risks to the growing fetus.
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